Brief: Tianjin Development Posts FY Total Revenue From Ops For Tianjin Lisheng Pharmaceutical RMB1.39 Bln
10/03/2026 24:54
March 10 (Reuters) - Tianjin Lisheng Pharmaceutical Co Ltd 002393.SZ: FY TOTAL REVENUE FROM OPERATIONS FOR TIANJIN LISHENG PHARMACEUTICAL RMB1.39 BILLION FY PRELIM NET PROFIT AFTER EXTRAORDINARY ITEMS ATTRIBUTABLE FOR TIANJIN LISHENG PHARMACEUTICAL RMB169.1 MILLION Further company coverage: 002393.SZ ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tianjin Development Holdings
See all newsHong Kong's Tianjin Development HY revenue on lower pharmaceutical, utilities sales
Brief: Tianjin Development Says Teng Fei Resigns As Chairman And Executive Director
Brief: Tianjin Development Says H1 2026 Net Profit Seen At RMB 73-83 Million For Tianjin Lisheng Pharmaceutical
Brief: Tianjin Development Says Lisheng Pharmaceutical Subscribes To Investment Products Totaling RMB180 Million
Brief: Tianjin Development Says Tianjin Lisheng Pharmaceutical QTRLY Operating Income RMB 332.28 Mln